)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Autolus Therapeutics (AUTL) investor relations material
Autolus Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary12 Aug, 2025
Executive summary
Achieved $20.9M in Q2 2025 US product sales for AUCATZYL, with 46 US centers activated and over 90% coverage of US medical lives, driven by strong demand and positive physician feedback.
Conditional marketing authorizations received in the UK and EU in Q2 2025, but no EU sales expected in 2025-2026 due to pricing, reimbursement, and orphan status challenges.
Long-term FELIX study data presented at EHA 2025 showed durable responses and favorable safety for AUCATZYL in r/r B-ALL, with 38.4% of responders in ongoing remission at 32.8 months median follow-up.
Pipeline advancing with pivotal trials in lupus nephritis and first-in-human progressive MS trial expected to start by year-end 2025.
Real-world data and clinical trial progress support further market access and label expansion efforts.
Financial highlights
Q2 2025 net product revenue was $20.9M; six months ended June 30, 2025, revenue totaled $29.9M.
Cost of sales in Q2 2025 was $24.4M, including deferred revenue and royalties; gross margin remained negative.
R&D expenses decreased to $27.4M in Q2 2025 (down from $36.6M YoY); SG&A expenses rose to $30.3M (from $21.9M YoY) due to commercialization.
Net loss for Q2 2025 was $47.9M, improved from $58.3M YoY; basic and diluted net loss per share was $(0.18) versus $(0.22) in Q2 2024.
Cash, cash equivalents, and marketable securities totaled $454.3M at June 30, 2025, down from $588M at year-end, impacted by operating cash use and delayed R&D tax credit.
Outlook and guidance
No EU sales expected in 2025-2026; focus remains on disciplined, country-by-country market access and pricing negotiations.
Pivotal trials in lupus nephritis and progressive MS expected to initiate by year-end 2025; SLE Phase 1 and pediatric ALL data anticipated in H2 2025.
Cash and marketable securities expected to fund operations for at least 12 months from issuance; management believes resources are sufficient for near-term objectives.
US center expansion to 60+ targeted by year-end, with CMS-related enrollment impacts expected to resolve by Q4.
Why is Autolus putting the Germany launch on hold?
Assess the impact of NICE's ACD on UK market access.
Elaborate on the delayed R&D tax credit from the UK HMRC.
How will CMS split reimbursement impact enrollment?
What's the long-term strategy for obe-cel?
Quantify impact of out-of-spec products on COGS.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Autolus Therapeutics earnings date
Q3 202511 Nov, 2025
Next Autolus Therapeutics earnings date
Q3 202511 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company engaged in the development of advanced T-cell therapies for the treatment of cancer. The company leverages its proprietary technologies to engineer CAR T-cell therapies aimed at providing life-changing benefits to patients with various cancer types. Some of their key clinical-stage programs focus on therapies for conditions such as adult acute lymphoblastic leukemia and multiple myeloma. Autolus was founded in 2014, following innovative developments in cell programming technology at University College London. The company is headquartered in London, United Kingdom, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage